Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02939651 · ClinicalTrials.gov registry record · Phase 2
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumors, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02939651 is a Phase 2 study of Neuroendocrine Tumors that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 21 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02939651, a Phase 2 study of Neuroendocrine Tumors, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melanoma and for metastatic non-small cell lung cancer. However, it is not approved for treatment of metastatic high-grade neuroendocrine tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (2)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-26 |
| Est. Completion | 2020-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02939651
The ClinicalTrials.gov registry entry for NCT02939651 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (88% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02939651 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT02939651 about?
NCT02939651 is a clinical study titled "A Study of Pembrolizumab in Patients With Neuroendocrine Tumors". The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melano...
What is the current status of trial NCT02939651?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2016-10-26. Estimated completion is 2020-03.
What conditions does trial NCT02939651 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT02939651?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02939651?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02939651 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.